Reset filters
  • 2 September 2008

Raltegravir may cause temporary worsening of pre-existing depression

Read the article
  • 2 September 2008

Etravirine (Intelence) approved in Europe for treatment-experienced patients

Read the article
  • 19 August 2008

Next generation first-line NNRTI, rilpivirine (TMC278) potent; lowest dose better-tolerated than efavirenz at 96 weeks

Read the article
  • 15 August 2008

Heat-stable ritonavir tablet equivalent to soft gel capsule; may be approved next year

Read the article
  • 8 August 2008

Two new NNRTIs look promising in early clinical trials

Read the article
  • 7 August 2008

Two novel immune therapies in early investigation: autologous dendritic cells and CD4 zeta gene-modified T cells

Read the article
  • 6 August 2008

Slowing CD4 cell decline with IL-2 allows HIV treatment to be deferred by 92 weeks

Read the article
  • 6 August 2008

Raltegravir versus efavirenz in treatment-naïves at 96 weeks: continued efficacy and fewer adverse effects

Read the article
  • 23 July 2008

Gilead now testing ritonavir replacement in human studies

Read the article

Receive the latest HIV research and conference news

Complete this form to receive regular email bulletins including the latest HIV research and conference news from aidsmap and/or updates from Terrence Higgins Trust.

Get regular email bulletins

Please let us know how you'd like to be contacted by ticking the options below.